Kisspeptin-10: benefits, side effects, dosage in studies and what the research shows

Kisspeptins are peptides produced from the KISS1 gene, which was first studied as a suppressor of cancer spread in melanoma. In 2001 two groups independently showed that its product is the natural ligand of an orphan receptor, GPR54 (now called KISS1R): a Japanese team isolated a 54-amino-acid form from human placenta and named it metastin ^[1], and a Belgian team isolated 54-, 14- and 13-amino-acid forms and named them kisspeptins ^[2]. All forms share the same final 10 amino acids, and that 10-amino-acid fragment, kisspeptin-10, is the minimal sequence with full activity at the receptor ^[3][8].

The importance of kisspeptin for human reproduction became clear in 2003, when people with inactivating mutations in GPR54 were found to have failed puberty (hypogonadotropic hypogonadism), and mice lacking the receptor showed the same defect ^[4].

Most searches for “kisspeptin” are about the hormone family as a whole, not one kisspeptin peptide. Kisspeptin-54 is the main circulating form in humans ^[12], and it has been used in most of the therapeutic trials. Kisspeptin-10 is the shortest fully active form and is the one most research peptide vendors sell. This guide says which form each study used, because results from one should not be assumed for the other. Kisspeptin analogues designed to last longer, such as MVT-602, are separate drugs again ^[23].

Kisspeptin acts on KISS1R receptors on GnRH neurons in the hypothalamus. This triggers GnRH release, which in turn stimulates the pituitary to release luteinising hormone (LH) and follicle-stimulating hormone (FSH), and these drive testosterone and oestrogen production and ovulation ^[5]. Because it works upstream of GnRH, it depends on the person’s own hypothalamus and pituitary being functional, which is why it is being studied as a diagnostic test.

Kisspeptin-10 is cleared from the blood very quickly. In male mice, its half-life was about 4 minutes compared with about 32 minutes for kisspeptin-54, and repeated kisspeptin-10 injections did not reproduce the sustained LH rise seen after a single kisspeptin-54 dose ^[8].

In people, the plasma half-life of kisspeptin-54 was measured at about 27.6 minutes in men given an intravenous infusion ^[11]. We found no published human half-life for kisspeptin-10 in the abstracts we read, and no measurement of its bioavailability after subcutaneous injection.

Kisspeptin research is an active academic field, led largely by groups in London, Edinburgh and Boston. Much of the therapeutic work, such as triggering egg maturation in IVF, uses the longer kisspeptin-54 rather than kisspeptin-10; for example, a phase 2 randomised trial in 62 women at high risk of ovarian hyperstimulation syndrome found that a second dose of kisspeptin-54 improved egg yield ^[9]. Results for kisspeptin-54 should not be assumed to apply to kisspeptin-10.

The sections below group the human research by the questions people ask: effects in men, effects in women, IVF, sexual desire, and how kisspeptin compares with other hormones and drugs.

Yes, in the short term and in study settings. With kisspeptin-54, a 90-minute intravenous infusion in six healthy men raised mean LH from 4.2 to 10.8 U/L and mean testosterone from 21.7 to 24.9 nmol/L compared with saline ^[11]. With kisspeptin-10, intravenous boluses and infusions raised LH and testosterone in healthy men (see Human studies) ^[5], and a 1 µg/kg bolus raised LH in young, middle-aged and older men but raised testosterone significantly only in the young adults, suggesting the testes respond less with age ^[16].

How much does kisspeptin increase testosterone in men with low levels? In a proof-of-concept study in men with type 2 diabetes and mildly low testosterone, an 11-hour kisspeptin-10 infusion at 4 µg/kg per hour raised LH from 3.9 to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L in four men ^[15]. In three healthy men given a continuous 24-hour kisspeptin-10 infusion at 12.5 µg/kg per hour, LH rose five- to eightfold, peaked at 12 to 20 hours and then fell by 13 to 47% while the infusion continued; testosterone rose modestly ^[17]. These were small studies of hours to days. None tested kisspeptin as a treatment for low testosterone.

Responses in women depend on the phase of the menstrual cycle (see Human studies) ^[6]. In women with hypothalamic amenorrhoea, whose periods have stopped because the brain’s reproductive signal is suppressed, twice-daily subcutaneous kisspeptin-54 at 6.4 nmol/kg raised LH by about 24 IU/L on day 1, but by only 2.5 IU/L on day 14, showing that repeated dosing caused desensitisation (tachyphylaxis) ^[14]. Kisspeptin benefits for women’s fertility are being studied mainly through IVF, not through daily use.

The best-known kisspeptin trials are in IVF, and all of them used kisspeptin-54, not kisspeptin-10. In 2014, a single subcutaneous injection of kisspeptin-54 (1.6 to 12.8 nmol/kg) triggered egg maturation in 53 women having IVF; embryos were transferred in 92% and the clinical pregnancy rate was 23% ^[12]. In a 2015 phase 2 randomised trial in 60 women at high risk of ovarian hyperstimulation syndrome (OHSS), egg maturation occurred in 95%, the live birth rate per transfer was 45%, and no woman developed moderate, severe or critical OHSS ^[13]. A second dose improved egg yield in a further trial ^[9].

A review of this work describes kisspeptin as producing a more physiological trigger that may reduce the OHSS risk seen with human chorionic gonadotrophin (hCG) ^[22]. The trials were small, single-centre and not powered to compare pregnancy rates with standard triggers. Kisspeptin is not an approved IVF drug.

London researchers have tested intravenous kisspeptin-54 at 1 nmol/kg per hour for 75 minutes in people with hypoactive sexual desire disorder. In 32 women, it changed brain responses to erotic videos and attractive faces on MRI and was well tolerated ^[20]. In 32 men, it changed activity in sexual-processing brain regions and increased penile tumescence in response to sexual videos by up to 56% more than placebo ^[19]. These were single-visit laboratory studies. In a separate study of 95 men and women, the same infusion raised LH but did not change anxiety, cortisol, blood pressure or heart rate ^[21].

Kisspeptin-10 bodybuilding use rests on the testosterone rise described above. We found no study of kisspeptin on muscle, strength, body composition or athletic performance, and the testosterone increases in studies were modest and lasted hours to days ^[11][15].

In healthy men, intravenous bolus kisspeptin-10 caused a rapid, dose-dependent rise in LH, greatest at 1 µg/kg, with a smaller response at 3 µg/kg. A 22.5-hour infusion raised LH and testosterone, and a lower-dose infusion increased the frequency and size of LH pulses ^[5].

Responses differ by sex and cycle phase. A 2011 study found that kisspeptin-10 raised LH and FSH in men at doses as low as 0.3 to 1.0 nmol/kg, but in women in the early (follicular) phase of the menstrual cycle it did not change gonadotrophins even at high doses; it did raise them in women in the preovulatory phase ^[6].

A 2026 randomised, single-blinded, placebo-controlled study in healthy men tested longer use. A continuous subcutaneous infusion for five days kept testosterone raised but gonadotrophins returned to placebo levels, while daily eight-hour infusions over 12 days sustained rises in gonadotrophins; the receptor still responded to a bolus at the end ^[7].

These are small physiological studies in volunteers or patients in specialist centres. There are no trials showing kisspeptin-10 improves fertility, libido, testosterone deficiency or body composition as a treatment.

Other kisspeptin-10 studies in people include a 2025 study in 12 healthy adults in which a 0.24 nmol/kg intravenous bolus raised blood oxytocin by about 19% at 10 minutes, more in men than in women ^[24]. Kisspeptin-10 is being used as a research tool to probe hormone systems, which is different from being developed as a treatment.

It depends on the endpoint. LH rises within minutes of an intravenous kisspeptin-10 bolus ^[5]. After a subcutaneous kisspeptin-54 injection in women with hypothalamic amenorrhoea, the maximal LH rise came within 4 hours ^[14]. Under a continuous kisspeptin-10 infusion, LH peaked after 12 to 20 hours ^[17]. In IVF, eggs were collected 36 hours after the kisspeptin-54 trigger ^[12]. Any effect on libido, fertility or wellbeing from repeated self-injection has not been studied, and repeated or continuous exposure can blunt the response ^[7][14].

Human studies gave kisspeptin by intravenous injection or infusion, or by subcutaneous injection or infusion ^[5][6][7]. A kisspeptin nasal spray has been tested once: in a 2025 randomised, placebo-controlled crossover study, intranasal kisspeptin-54 at 12.8 nmol/kg raised LH in healthy men and women and in women with hypothalamic amenorrhoea, with no side effects reported, and the spray was stable for up to 60 days at 4 °C ^[18]. That study used kisspeptin-54, not kisspeptin-10.

We found no human study of kisspeptin tablets, pills or oral “kisspeptin supplements”. Kisspeptin is a peptide, and nothing in the literature we read suggests oral products deliver it intact.

Published human studies used intravenous boluses of 0.01 to 3.0 µg/kg and infusions of 1.5 to 4 µg/kg per hour in men ^[5]; intravenous boluses up to 10 nmol/kg, subcutaneous boluses up to 32 nmol/kg and infusions up to 720 pmol/kg per minute in women ^[6]; and subcutaneous infusions of 150 to 180 nmol per hour in men for 5 to 12 days ^[7]. All were given in supervised research settings; these are not recommended doses.

Kisspeptin dosage for men in other kisspeptin-10 studies included a 0.3 µg/kg intravenous bolus and an 11-hour infusion of 4 µg/kg per hour ^[15], a 1 µg/kg intravenous bolus ^[16] and a 24-hour infusion of 12.5 µg/kg per hour ^[17]. Kisspeptin dosage for women in kisspeptin-54 studies included single subcutaneous IVF triggers of 1.6 to 12.8 nmol/kg ^[12][13], twice-daily injections of 6.4 nmol/kg ^[14] and 12.8 nmol/kg by nasal spray ^[18]. The two forms differ in size and potency, so their doses are not interchangeable.

Kisspeptin-10 has a molecular weight of about 1,302 g/mol, so 1 nmol is about 1.3 µg. For vial questions, such as kisspeptin-10 5mg reconstitution, the concentration is the peptide amount divided by the liquid volume; our peptide calculator and bacteriostatic water guide show the arithmetic. Vendor “kisspeptin protocols” and daily dosing schedules are not drawn from these studies.

The published physiological studies did not report serious adverse effects in their abstracts, but they involved small numbers of people over short periods ^[5][6][7]. A known pharmacological issue is that continuous exposure can blunt the gonadotrophin response: in the 2026 study, gonadotrophins returned to placebo levels during a five-day continuous infusion ^[7]. Kisspeptin-10 raises reproductive hormones, so effects on fertility, menstrual cycles and hormone-sensitive conditions cannot be excluded.

Reported kisspeptin side effects in the published studies are few. The nasal study reported no side effects or adverse events ^[18], the study in women with low sexual desire reported no adverse effects ^[20], and the IVF trial in high-risk women found no moderate or severe OHSS ^[13]. The large anxiety study found no change in anxiety, blood pressure or heart rate ^[21]. These are short, supervised studies with pharmaceutical-grade peptide. For kisspeptin side effects in men and women using research products for weeks, there are no data, and desensitisation with repeated dosing is well documented ^[14].

The US FDA lists kisspeptin-10 in category 2 of bulk drug substances for pharmacy compounding, meaning substances that may present significant safety risks; its stated concerns are a possible risk of immunogenicity for certain routes of administration and complexities with peptide-related impurities and characterisation (as of April 2026) ^[10].

hCG is a hormone similar to LH in structure and function ^[26], so it acts directly on the ovaries or testes. Kisspeptin acts at the top of the chain, on GnRH neurons, and so depends on a working hypothalamus and pituitary. In IVF, the review literature describes kisspeptin as a potentially safer trigger than hCG because it reduces OHSS risk ^[22]. hCG is a controlled Class C drug in the UK ^[27]. We found no study of kisspeptin and hCG used together.

Gonadorelin is a name for GnRH itself, the ten-amino-acid hormone that stimulates the pituitary to release LH and FSH ^[25]. Kisspeptin works one step earlier, by releasing the body’s own GnRH. Enclomiphene is one of the two isomers of clomiphene, a small-molecule drug that acts as an oestrogen agonist or antagonist depending on the tissue ^[28]; it is taken by mouth and is not a peptide. We found no study comparing kisspeptin with gonadorelin or enclomiphene head to head.

Both are discussed for libido, but they work differently. PT-141 (bremelanotide) is a melanocortin receptor agonist, approved in the US as Vyleesi for premenopausal women with acquired, generalised hypoactive sexual desire disorder, and not approved for men ^[29]. Kisspeptin acts on the reproductive hormone axis; its libido research is limited to the single-visit kisspeptin-54 brain studies above ^[19][20]. There are no head-to-head trials.

Kisspeptin-10 is not approved as a medicine in the UK, US, Canada, Australia or New Zealand, and we found no approval elsewhere. In the US, its category 2 listing means it should not be used by compounding pharmacies under FDA’s interim policies ^[10]. See our legal status overview and the US and UK pages.

Is kisspeptin FDA approved? No form of kisspeptin is an FDA-approved drug. In New Zealand, kisspeptins are classified as prescription medicines, and Medsafe’s May 2026 consumer advisory named kisspeptin among unapproved peptide products it warned consumers about ^[30]. See the New Zealand legal status page.

Research kisspeptin-10 is usually sold as a freeze-dried powder. Because it is broken down quickly in the body ^[8], solution stability should not be assumed; see our peptide storage guide.

You can compare prices, learn how to read a COA, and see our list of third-party tested suppliers. For another peptide that acts on sexual function through the brain, see PT-141.

Country pages list kisspeptin-10 in the US and kisspeptin-10 in the UK. A listing is not a statement that a product is legal or suitable for use. Check that a vendor publishes batch results; see suppliers with published COAs and how to spot a fake peptide supplier.